Skip to main content
Fig. 3 | Journal of Translational Medicine

Fig. 3

From: The gut microbiota participates in the effect of linaclotide in patients with irritable bowel syndrome with constipation (IBS-C): a multicenter, prospective, pre-post study

Fig. 3

The efficacy of linaclotide in the treatment of IBS-C was related to its ability to modulate the gut microbiota. A Changes in alpha diversity indices. B Principal coordinate analysis (PCoA) of the gut microbiota. C, D The abundance of Firmicutes at the phylum level and that of Blautia at the genus level were greater after 6 weeks of treatment than at 0 weeks. E Linear discriminant analysis (LDA) was used to estimate the impact of the abundance of each component (genus) on the effects. F Community heatmap generated using color gradients to represent the size of the data in a two-dimensional matrix or table and to present community species composition information. ACE, Jaccard, and the abundances of Firmicutes and Blautia were adjusted for the IBS-SSS baseline score, sex, age, BMI, education, basic disease status, and nutrient status by repeated-measures ANOVA

Back to article page